咪唑立宾治疗儿童频复发型原发肾病综合征45例疗效观察

发布时间：2018-07-27 12:25

【摘要】：目的观察咪唑立宾(MZR)对儿童频复发型原发肾病综合征的疗效。方法将2013年4月至2015年1月中南大学湘雅二医院儿童医学中心儿童肾脏专科的住院或门诊登记完整的儿童频复发型原发肾病综合征45例纳入研究,观察对照组(雷公藤+泼尼松)24例和治疗组(咪唑立宾+泼尼松)21例1年内患儿复发次数、波尼松用量、肾小球滤过率、血清白蛋白、尿蛋白、尿酸等指标的变化。结果予以MZR治疗后,治疗组患儿复发次数减少,泼尼松有效用量下降、肾小球滤过率无下降、血清白蛋白水平上升、尿蛋白减少、尿酸水平无明显变化。结论 MRZ是治疗儿童频复发型原发肾病综合征的有效药物。
[Abstract]:Objective to observe the effect of midazolipin (MZR) on recurrent primary nephrotic syndrome in children. Methods from April 2013 to January 2015, 45 children with recurrent primary nephrotic syndrome were enrolled in the study. 24 cases of control group (Tripterygium wilfordii prednisone) and 21 cases of treatment group (midazolipin prednisone) within one year were observed the changes of recurrence times, dosage of Bonisone, glomerular filtration rate, serum albumin, uric acid and so on. Results after MZR treatment, the number of recurrence, the effective dosage of prednisone, the glomerular filtration rate, the serum albumin level, the urinary protein level and the uric acid level in the treatment group were decreased. Conclusion MRZ is an effective drug for the treatment of recurrent primary nephrotic syndrome in children.
【作者单位】：中南大学湘雅二医院儿童医学中心;湖南省人民医院医务部;
【分类号】：R726.9

【参考文献】